AK
AKTX.US Akari Therapeutics PLC
- Market cap
- USD 15.9M
- P/E
- -
- P/B
- 0.82x
- ROE
- -183.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AKTX.US undervalued?
Graham numberThe Graham number of Akari Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Akari Therapeutics PLC fundamental analysis
No fundamental analysis for Akari Therapeutics PLC yet.
Akari Therapeutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric…
Full company profileAkari Therapeutics PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Akari Therapeutics PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -39.8K | 0.00 | -35.8K | -19.2K | -8.91K | -4.13K | -3.71K | -4.00K | -14.0K | - | - |
| Operating Income | -27.2M | -35.0M | -20.0M | -24.9M | -18.0M | -17.2M | -23.1M | -16.8M | -21.6M | -17.3M | -33.4M |
| EBITDA | -27.2M | -37.2M | -16.4M | -24.7M | -18.0M | -17.4M | -17.7M | -10.0M | -19.5M | -17.4M | -32.9M |
| Net Income | -18.1M | -27.9M | -20.0M | -16.8M | -17.1M | -17.4M | -17.7M | -10.0M | -19.8M | -17.3M | -32.1M |
| EPS | -61,704 | -2.24 | -51,818 | -36,863 | -21,650 | -16,239 | -11,377 | -4,090 | -3,314 | -822 | -9.67 |
| Balance Sheet | |||||||||||
| Total Assets | 45.9M | 29.1M | 16.5M | 10.3M | 14.6M | 11.6M | 13.8M | 4.36M | 50.6M | 47.9M | 36.6M |
| Total Liabilities | 11.8M | 9.07M | 3.08M | 6.47M | 5.22M | 6.09M | 12.0M | 4.58M | 28.3M | 19.6M | 19.1M |
| Shareholders' Equity | 34.1M | 20.0M | 13.4M | 3.84M | 9.38M | 5.55M | 1.79M | -229K | 22.2M | 28.3M | 17.5M |
| Cash & Short-term Investments | 44.1M | 28.1M | 5.97M | 5.73M | 14.1M | 9.36M | 13.3M | 3.85M | 2.60M | 5.20M | 5.74M |
| Total Debt | - | - | - | - | - | - | - | - | 3.26M | 754K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -24.6M | -31.6M | -22.5M | -12.9M | -17.0M | -18.8M | -21.5M | -16.4M | -12.6M | -10.6M | -13.1M |
| Capital Expenditure | 54.8K | 36.9K | 36.9K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -24.7M | -31.6M | -22.5M | -12.9M | -17.0M | -18.8M | -21.5M | -16.4M | -12.6M | -10.6M | -13.1M |
| Ratios | |||||||||||
| ROE | -53.2% | -139.8% | -149.1% | -439.2% | -182.0% | -313.7% | -991.0% | - | -89.0% | -61.1% | -183.6% |
| ROA | -39.5% | -96.1% | -121.3% | -163.4% | -117.0% | -149.6% | -128.3% | -229.8% | -39.1% | -36.1% | -87.9% |
| Debt to Equity | - | - | - | - | - | - | - | - | 0.15x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Akari Therapeutics PLC dividends
Akari Therapeutics PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Mar 31, 2026.
Who owns Akari Therapeutics PLC
- Insiders 16.32%
- Institutions 7.78%
- Public & others 75.90%
- Shares outstanding 2.29M
- Free float 1.43M
Top funds holding AKTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| LUX IM Global Medtech HX | 1.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding AKTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mmcap International Inc. Spc | 100K | 4.38% | 0.00% | Jun 2026 |
| Cresset Asset Management, LLC | 20.6K | 0.90% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 15.5K | 0.68% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 13.7K | 0.60% | 0.00% | Jun 2026 |
| IFP Advisors, LLC | 181.00 | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 14.00 | 0.00% | +180.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Truvestments Capital LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Akari Therapeutics PLC company profile
- Company name
- Akari Therapeutics PLC
- Ticker
- AKTX.US
- Exchange
- USA Stocks
- Listed since
- Sep 21, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5
- Fiscal year end
- December
- Address
- 401 East Jackson Street, Tampa, FL, United States, 33602
- Phone
- 929 274 7510
- Website
- akaritx.com
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Akari Therapeutics PLC management
4- Mr. Abizer GaslightwalaCEO, President & Director · born 1974
- Mr. Kameel D. FaragInterim Chief Financial Officer · born 1978
- Dr. Satyajit Mitra Ph.D.Executive Director & Head of Oncology · born 1975
- Mr. Vatnak Vat-Ho M.B.A.Chief Business Officer